BNGO Stock Price: BioNano Genomics Inc. retreats, starts week in the red

NASDAQ:BNGO dips, despite another analyst upgrade.
Micro-cap healthcare stocks provide mix results for Nasdaq.

Stocks Reporter FXStreet

NASDAQ:BNGO fell on Monday, despite more news that should keep investors bullish on the healthcare company. The stock price dropped 8.64% to finish the trading session at $0.8131 per share, nearly wiping out the 14% rise from Friday of last week. BioNano briefly touched a low of $0.78 before finishing out strong, climbing back above $0.80 to end the day. Surprisingly, there was a higher than average volume trading throughout the day, which is another relatively positive sign for investors who have remained loyal to the company.

BNGO Stock Forecast: Dips, despite optimism, further analyst upgrade

The micro-cap healthcare sector produced another mixed day of results, even as the Nasdaq rebounded from the mini correction to end last week. BioNano Genomics Inc. rivals Pacific Biosciences of California (NASDAQ: PACB) rose on Monday, despite a Zacks Consensus Estimate report that Wall Street is expecting a 43.8% year over year decline in revenues. Other industry companies like Progenity Inc. (NASDAQ:PROG), Predictive Oncology Inc. (NASDAQ:POAI) and Precipio (NASDAQ:PRPO) all remained relatively flat.

Earlier on Monday, a report from Oppenheimer stated that 5-Star healthcare analyst Kevin DeGeeter doubled down on his stock price upgrade, giving BioNano an 'Outperform' rating and a new price target of $1.50 per share. While this is lower from his price target earlier in the year of $1.83, investors should still feel optimistic that there is quite a bit of sentiment on Wall Street that Bionano Genomics Inc. has a bright future on coronavirus vaccine development. Along with their usual work in human genetics, BioNano has been in the news recently for its work in discovering commonalities in the genetic variants of young male patients who had severe cases of COVID-19.

Author

Stocks Reporter

FXStreet

British Pound eases to 1.3450 area following downwardly revised Manufacturing PMI data

The British Pound is trimming previous gains against the US Dollar on Monday, returning to the mid-range of the 1.3400s down from fresh seven-week highs, above 1.3500 earlier on the day. Weaker-than-expected UK manufacturing data added pressure on the Pound, which rallied at the Asian session opening, amid news of a halt to the hostilities in Iran.

EUR/USD struggles above 1.1500 despite USD weakness

EUR/USD struggles with its recovery above 1.1500 in European trading on Monday, despite broad US Dollar weakness and improved risk sentiment. The USD loses traction following US President Trump's call off an attack on Iran and that talks between the two sides would happen on Monday. Traders will closely monitor the developments surrounding US-Iran negotiations and US ISM PMI data.

Gold extends range play below $4,100 as rebounding USD meets receding Fed hike bets

Gold struggles to capitalize on a modest weekly bullish gap opening, and remains below the $4,100 mark heading into the European session. The US Dollar stages a modest recovery from its lowest level since June 17, which is seen capping the upside for the commodity. The upside for the USD, however, seems limited amid renewed hopes for a US-Iran peace deal and receding US Fed rate-hike expectations.

Week ahead: US payrolls report and AI earnings to keep investors on edge

After the Fed decision, NFP report awaited for more rate hike clues. Employment also on the agenda in Canada and New Zealand. Chinese trade and Japanese wage data to be watched too. But Iran and AI headlines to remain in driver’s seat for risk sentiment.

Solana risks a steeper decline below $70 despite steady ETF inflows

Solana (SOL) is trading in the red, losing bullish momentum and remaining capped below its 50-day Exponential Moving Average at $75.68. SOL-focused Exchange Traded Funds show resilience with a monthly inflow of $14.62 million in July, while the near-term retail support wanes with the funding rate turning negative.

9-3: Is the Federal Reserve’s vote tally Warsh's new forward guidance?

The rate did not move. Neither did the statement, and that’s the more interesting fact. Set the July 29 Federal Open Market Committee (FOMC) statement beside the one issued on June 17, and the two documents are identical apart from a single verb and a paragraph at the bottom naming three dissenters.